Hypertrophic pulmonary osteoarthropathy: Control of pain and symptoms with pamidronate

Clinical Rheumatology

Volumn 23, Issue 4, 2004, Pages 330-332

  Amital, Howard ^a   Applbaum, Yaakov H ^a   Vasiliev, Lena ^a   Rubinow, Alan ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Bisphosphonates; Cyanotic heart disease; Hypertrophic pulmonary osteoarthropathy; Pain; Pamidronate

Indexed keywords

ALDOSTERONE; AMINOPHYLLINE; ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; DIGOXIN; ENALAPRIL; FUROSEMIDE; PAMIDRONIC ACID; THIAMINE;

ADULT; ARTICLE; BONE RADIOGRAPHY; CASE REPORT; CHRONIC LUNG DISEASE; CLINICAL FEATURE; CYANOTIC HEART DISEASE; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HUMAN; HYPERTROPHIC OSTEOARTHROPATHY; LEG DISEASE; LEG PAIN; LUNG CARCINOMA; LUNG METASTASIS; PAIN ASSESSMENT; PRIORITY JOURNAL; SINGLE DRUG DOSE;

EID: 4444265541     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-004-0941-4     Document Type: Article

References (11)

1. Semple T, McCluskie RA (1955) Generalized hypertrophic osteoarthropathy in association with bronchial carcinoma. Br Med J 1:754-759
2. Garske LA, Bell SC (2002) Pamidronate results in symptom control of hypertrophic pulmonary osteoarthropathy in cystic fibrosis. Chest 121:1363-1364
3. Martinez-Lavin M (1992) Cardiogenic hypertrophic osteoarthropathy. Clin Exp Rheumatol 10 [Suppl 7]:19-21
4. Pineda C, Fonseca C, Martinez-Lavin M (1990) The spectrum of soft tissue and skeletal abnormalities of hypertrophic osteoarthropathy. J Rheumatol 17:626-632
5. Reid IR (2003) Bisphosphonates: new indications and methods of administration. Curr Opin Rheumatol 15:458-463
6. Suzuma T, Sakurai T, Yoshimura G, Umemura T, Tamaki T, Yoshimasu T, Naito (2001) Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma. Anticancer Drugs 12:731-734
7. Silveri F, De Angelis R, Argentati F, Brecciaroli D, Muti S, Cervini C (1996) Hypertrophic osteoarthropathy: endothelium and platelet function. Clin Rheumatol 15:435-439
8. Silveira LH, Martinez-Lavin M, Pineda C, Fonseca MC, Navarro C, Nava A (2000) Vascular endothelial growth factor and hypertrophic osteoarthropathy. Clin Exp Rheumatol 18:57-62
9. Abe Y, Kurita S, Ohkubo Y, et al. (2002) A case of pulmonary adenocarcinoma associated with hypertrophic osteoarthropathy due to vascular endothelial growth factor. Anticancer Res 22:3485-3488
10. Luckman SP, Hughes DE, Coxon FP, Russell G, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581-589
11. Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. Biochem Biophys Res Commun 264:108-111